The agent for the treatment of iron deficiency states. Polynuclear iron centers (III) hydroxide are surrounded by a plurality of outside noncovalently bound sucrose molecules. The result is a complex, a molecular weight of approximately 43 kD, consequently its excretion by the kidneys in unchanged form impossible. This complex is stable in physiological conditions does not release iron ions. The iron in this complex is associated with a structure similar to a natural ferritin.
After a single on / in a dose of containing 100 mg of iron, C max iron, on average, 538 micromoles, is achieved after 10 min after injection. V d central chamber virtually completely corresponds to the volume of serum – about 3 liters. V d at steady state is about 8 liters (which indicates the distribution of the low iron in body fluids). Due to the low stability of iron sucrose in comparison to transferrin, a competitive exchange of iron is observed in favor of transferrin. As a result, for 24 h transferred about 31 mg of iron (III). T 1/2 -. About 6 hours in the first 4 hours kidneys displayed less than 5% of the total iron clearance. After 24 h, serum iron is returned to the original (before the administration) value, and about 75% sucrose leaves the bloodstream.
Ferric III hydroxide sacharose complex
Mefar Ilach A.SH Sanayi, Turkey
1 mL contains:
Active ingredient: iron III (in the form of hydroxide sucrose complex) – 20 mg,
Excipients: sodium hydroxide – to pH 10.5-11.1, water d / and – up to 1 ml.
Iron deficiency: fast filling, if necessary
gland; intolerance to oral iron supplementation or
non-compliance with treatment; in the presence of active inflammatory
intestinal diseases when oral iron preparations are ineffective.
Anemia is not associated with iron deficiency; signs of iron overload
(Hemosiderosis, hemochromatosis); disturbance of iron utilization process; I
trimester of pregnancy; Hypersensitivity to the active substance.
From the nervous system: very rarely – dizziness, headache, loss of consciousness, paresthesia.
With the cardiovascular system: very rarely – palpitations, tachycardia, decreased blood pressure, kollaptoidnye state, feeling hot, “tides” of blood to the face.
On the part of the respiratory system: very rarely – bronchospasm, dyspnea.
From the digestive system: very rarely – spilled abdominal pain, epigastric pain, diarrhea, dysgeusia, nausea, vomiting.
For the skin: very rarely – erythema, pruritus, rash, pigmentation disorders, excessive sweating.
On the part of the musculoskeletal system: very rarely – arthralgia, back pain, swelling of joints, myalgia, pain in the limbs.
Allergic reactions: very rare – anaphylactoid reactions, swelling of the face, swelling of the larynx.
General reactions: very rarely – fatigue, chest pain, feeling of heaviness in the chest, fatigue, peripheral edema, malaise, pallor, fever, chills.
Local reactions: very rarely – pain and swelling at the injection site.
How to accept, acceptance rate and dosage
Administered alone / in (slow drip or bolus) or in the venous portion of the dialysis system. Not designed for a / m introduction. Unacceptable cross-sectional administering the full therapeutic dose.
Before the introduction of the first therapeutic dose is necessary to assign a test dose. If you are experiencing the phenomenon of intolerance during the observation period, the introduction should be stopped immediately.
The dose is calculated individually in accordance with the general lack of iron in the body by a special formula.
Ferric III hydroxide sacharose complex
should not be used simultaneously with the dosage forms of iron for
ingestion, since reduced iron absorption from the gastrointestinal tract. Treatment
oral iron preparations can begin no earlier than 5 days
after the last injection.
To use caution in patients with asthma, eczema, polyvalent allergy, allergic reactions to other parenteral iron preparations; patients with low serum iron binding capacity and / or folate deficiency; patients with hepatic insufficiency, acute or chronic infectious diseases, while elevated levels of ferritin in serum due to the fact that iron on parenteral administration may have an adverse effect in the presence of bacterial or viral infection.
Applied only when confirming the diagnosis of anemia corresponding laboratory data (e.g., results of determination of serum ferritin and hemoglobin or hematocrit, number of erythrocytes and their parameters – mean cell volume, the average content of hemoglobin).
B / in iron preparations can cause allergic or anaphylactic reactions which may be potentially life threatening.
The higher incidence of adverse side reactions (in particular – blood pressure decrease), which may also be heavy and to be associated with increasing dose.